{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:02:47Z","timestamp":1774076567934,"version":"3.50.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the last decade, immunotherapy has emerged as a new treatment modality in cancer. The most success has been achieved with the class of checkpoint inhibitors (CPIs), antibodies that unleash the antitumor immune response. After the success in melanoma, numerous clinical trials are being conducted investigating CPIs in lung cancer and mesothelioma. The programmed death protein (PD) 1\u2013PD ligand 1\/2 pathway and cytotoxic T lymphocyte\u2013associated protein 4 are currently the most studied immunotherapeutic targets in these malignancies. In non\u2013small cell lung cancer, anti\u2013PD-1 antibodies have become part of the approved treatment arsenal. In small cell lung cancer and mesothelioma, the efficacy of checkpoint inhibition has not yet been proven. In this Concise Clinical Review, an overview of the landmark clinical trials investigating checkpoint blockade in lung cancer and mesothelioma is provided. Because response rates are around 20% in the majority of clinical trials, there is much room for improvement. Predictive biomarkers are therefore essential to fully develop the potential of CPIs. To increase efficacy, multiple clinical trials investigating the combination of cytotoxic T lymphocyte\u2013associated protein 4 inhibitors and PD-1\/PD ligand 1 blockade in lung cancer and mesothelioma are being conducted. Given the potential benefit of immunotherapy, implementation of current and new knowledge in trial designs and interpretation of results is essential for moving forward.<\/jats:p>","DOI":"10.1164\/rccm.201608-1755ci","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T10:41:05Z","timestamp":1488451265000},"page":"274-282","source":"Crossref","is-referenced-by-count":57,"title":["Checkpoint Blockade in Lung Cancer and Mesothelioma"],"prefix":"10.1093","volume":"196","author":[{"given":"Lysanne A.","family":"Lievense","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"},{"name":"Department of Pulmonary Medicine, Amphia Hospital, Breda, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Sterman","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, New York University (NYU) School of Medicine\/NYU Langone Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G.","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"},{"name":"Department of Pulmonary Medicine, Amphia Hospital, Breda, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"2026032023442244200_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non\u2013small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"2026032023442244200_bib3","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/annonc\/mdj910","article-title":"Small cell lung cancer","volume":"17","author":"Rosti","year":"2006","journal-title":"Ann Oncol"},{"key":"2026032023442244200_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","article-title":"Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non\u2013small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026032023442244200_bib5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib6","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non\u2013small-cell lung cancer: AVAPERL (MO22089)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non\u2013small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib8","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib10","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","article-title":"Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years\u2019 follow-up","volume":"20","author":"Sundstr\u00f8m","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1054\/bjoc.2000.1164","article-title":"Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent","volume":"83","author":"Pujol","year":"2000","journal-title":"Br J Cancer"},{"key":"2026032023442244200_bib12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0277-5379(87)90128-3","article-title":"Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy","volume":"23","author":"Postmus","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2026032023442244200_bib13","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O\u2019Brien","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib14","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2026032023442244200_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026032023442244200_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"2026032023442244200_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib19","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1158\/1078-0432.CCR-15-2998","article-title":"Nivolumab and pembrolizumab for non\u2013small cell lung cancer","volume":"22","author":"Morgensztern","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026032023442244200_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11912-016-0544-7","article-title":"Immune checkpoint blockade: a new era for non\u2013small cell lung cancer","volume":"18","author":"Califano","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"2026032023442244200_bib21","doi-asserted-by":"crossref","first-page":"e27482","DOI":"10.4161\/onci.27482","article-title":"Immune checkpoint blockade in malignant mesothelioma: a novel therapeutic strategy against a deadly disease?","volume":"3","author":"Calabr\u00f2","year":"2014","journal-title":"OncoImmunology"},{"key":"2026032023442244200_bib22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib24","author":"Socinski"},{"key":"2026032023442244200_bib25","doi-asserted-by":"crossref","first-page":"LBA41_PR","DOI":"10.1093\/annonc\/mdw435.38","article-title":"Neoadjuvant anti-PD1, nivolumab, in early stage resectable non\u2013small-cell lung cancer","volume":"27","author":"Forde","year":"2016","journal-title":"Ann Oncol"},{"key":"2026032023442244200_bib26","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1\u2013positive, advanced non\u2013small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2026032023442244200_bib28","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non\u2013small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026032023442244200_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026032023442244200_bib31","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/jco.2015.33.15_suppl.7502","article-title":"Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028 [abstract]","volume":"33","author":"Ott","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib32","author":"Quispel-Janssen"},{"key":"2026032023442244200_bib33","author":"Alley"},{"key":"2026032023442244200_bib34","author":"Alley"},{"key":"2026032023442244200_bib35","author":"Kindler"},{"key":"2026032023442244200_bib36","author":"Besse"},{"key":"2026032023442244200_bib37","author":"Garassino"},{"key":"2026032023442244200_bib38","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non\u2013small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"2026032023442244200_bib39","author":"Barlesi"},{"key":"2026032023442244200_bib40","author":"Gadgeel"},{"key":"2026032023442244200_bib41","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non\u2013small cell lung cancer (NSCLC) [abstract]","volume":"33","author":"Rizvi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib42","author":"Garassino"},{"key":"2026032023442244200_bib43","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1200\/JCO.2016.34.15_suppl.9036","article-title":"Avelumab (MSB0010718C; anti\u2013PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression [abstract]","volume":"34","author":"Verschraegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib44","author":"Jerusalem"},{"key":"2026032023442244200_bib45","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti\u2013PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression [abstract]","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib46","first-page":"1927","article-title":"Relationship between overall survival and response or progression-free survival in advanced non\u2013small cell lung cancer patients treated with anti\u2013PD-1\/PD-L1 antibodies","volume":"11","author":"Shukuya","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib47","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1182\/blood-2011-11-388918","article-title":"Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells","volume":"119","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"2026032023442244200_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"2026032023442244200_bib49","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1126\/science.282.5397.2263","article-title":"Molecular basis of T cell inactivation by CTLA-4","volume":"282","author":"Lee","year":"1998","journal-title":"Science"},{"key":"2026032023442244200_bib50","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non\u2013small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib51","first-page":"JCO676601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"pii","author":"Reck","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease\u2013small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"key":"2026032023442244200_bib53","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2009.27.15_suppl.8071","article-title":"Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (PTs) with advanced non\u2013small cell lung cancer (NSCLC)","volume":"27","author":"Zatloukal","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib54","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2016.34.15_suppl.8502","article-title":"Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study [abstract]","volume":"34","author":"Kindler","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib55","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026032023442244200_bib56","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S1470-2045(13)70557-6","article-title":"Biomarkers for immune checkpoint inhibitors","volume":"15","author":"Lievense","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026032023442244200_bib57","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-16-0694","article-title":"Checkpoint immunotherapy: picking a winner","volume":"6","author":"Teng","year":"2016","journal-title":"Cancer Discov"},{"key":"2026032023442244200_bib58","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"2026032023442244200_bib59","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti\u2013PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026032023442244200_bib60","doi-asserted-by":"crossref","first-page":"e963413","DOI":"10.4161\/21624011.2014.963413","article-title":"Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1\/PD-L1 blockade","volume":"3","author":"Taube","year":"2014","journal-title":"OncoImmunology"},{"key":"2026032023442244200_bib61","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026032023442244200_bib62","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/JTO.0000000000000526","article-title":"Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?","volume":"10","author":"Kerr","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026032023442244200_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","article-title":"PD-L1 biomarker testing for non\u2013small cell lung cancer: truth or fiction?","volume":"4","author":"Grigg","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2026032023442244200_bib64","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026032023442244200_bib65","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"key":"2026032023442244200_bib66","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1073\/pnas.0813175106","article-title":"Anti\u2013CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026032023442244200_bib67","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/ijc.27755","article-title":"Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment","volume":"132","author":"Fransen","year":"2013","journal-title":"Int J Cancer"},{"key":"2026032023442244200_bib68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s13277-015-3885-1","article-title":"Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound","volume":"37","author":"Bugalho","year":"2016","journal-title":"Tumour Biol"},{"key":"2026032023442244200_bib69","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2016.34.15_suppl.3001","article-title":"CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC [abstract]","volume":"34","author":"Hellmann","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026032023442244200_bib70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non\u2013small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026032023442244200_bib71","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"2026032023442244200_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/196\/3\/274\/67149391\/ajrccm_196_3_274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/196\/3\/274\/67149391\/ajrccm_196_3_274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:44:53Z","timestamp":1774064693000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/196\/3\/274\/8499014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,8,1]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201608-1755ci","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,8,1]]}}}